Xeris Pharmaceuticals
- Market cap
- 1.84B
- P/E (TTM)i
- -104.23
- P/Bi
- -190.75
- EPSi
- 0.00
- Div yieldi
- 0.00%
- 52W posi
- 80%
Anonymous reader poll. Unscientific, not investment advice.
About Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
- Founded
- 2005
- CEO
- Mr. John P. Shannon
- Employees
- 435
- Headquarters
- Chicago, Illinois, United States of America
- Fiscal year end
- 12-31
- Website
- xerispharma.com
Company profile
- Exchange
- US
- Symbol
- XERS
- Market-cap rank
- #2862
- Listing date
- 2018-06-21
- Market cap
- 1.84B
- Float cap
- 1.78B
- Shares out
- 182.32M
- Float shares
- 176.07M
Sectors & themes
Quote time 2026-10-08 07:22:20 · For reference only, not investment advice and not tailored to your situation.